



P R O V I D E R B U L L E T I N

B T 2 0 0 5 1 2

J U N E 3 , 2 0 0 5

To: All Pharmacy Providers and Prescribing Practitioners

Subject: Changes to the Preferred Drug List

Note: The information referenced below is not directed to those providers rendering services in the risk-based managed care (RBMC) delivery system.

Overview

This bulletin announces the Preferred Drug List (PDL) decisions made at the May 27, 2005, Drug Utilization Review (DUR) Board meeting. These decisions were based on the recommendations from the Therapeutics Committee meeting held on May 6, 2005. Please refer to Table 1 for a summary of these changes. **These changes are effective June 28, 2005.**

The PDL can be accessed at www.indianapbm.com. Notice of the DUR Board meetings and agendas are posted on the Family and Social Services Administration (FSSA) Web site at <http://www.state.in.us/fssa/> under the tab titled **Calendar**. Information about the Therapeutics Committee and the PDL is available at <http://www.indianapbm.com>.

Please direct prior authorization requests and questions about the PDL to the ACS Clinical Call Center at 1-866-879-0106. Questions about this bulletin should be directed to the ACS Pharmacy Services Helpdesk at 1-866-645-8344.

Table 1 – Approved Changes to the PDL Effective June 28, 2005

Drug Class	Drug	PDL Status
Antiemetics	Kytril Injection	Non-Preferred
Brand Name Narcotics	fentanyl patches	Preferred
Brand Name Narcotics	oxycodone ER 80mg	Preferred
Brand Name Narcotics	Combunox	Non-Preferred
Brand Name Narcotics	Palladone	Non-Preferred – PA Criteria – Patient must have had previous analgesic therapy equivalent to a dose of 12mg hydromorphone per day for at least 30 days.
Skeletal Muscle Relaxants	dantrolene	Preferred
Smoking Deterrent Agents	bupropion	Preferred
Thiazolidinediones	Actos	Preferred – Remove current step edit
Thiazolidinediones	Avandia	Preferred – Remove current step edit
Proton Pump Inhibitors	Nexium IV	Preferred

(Continued)

Table 1 – Approved Changes to the PDL Effective June 28, 2005

Drug Class	Drug	PDL Status
Proton Pump Inhibitors	Zegerid 40mg oral suspension	Non-Preferred
H2 Receptor Antagonists	Zantac Effervescent	Non-Preferred
Urinary Tract Antispasmodics	Enablex	Non-Preferred
Platelet Aggregation Inhibitors	cilostazol	Preferred
Glaucoma Agents	Istalol	Non-Preferred
Non-Sedating Antihistamines	Allegra	Non-Preferred